Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
A Phase I-IIa trial to assess the safety and antitumor activity of autologous CD44v6 CAR T-cells in acute myeloid leukemia and multiple myeloma expressing CD44v6

Proposed period of release:
01/03/2019 to 31/03/2023

Name of the Institute(s) or Company(ies)
MolMed SpA, Via Olgettina 558 20132
Milano (Italy);

3. Is the same GMO release planned elsewhere in the Community?
Germany; Italy; Czech Republic;

Has the same GMO been notified elsewhere by the same notifier?

GMO characterization

GMO is a:
Other: mammal

Identity of the GMO:
Genus:Homo; Species:H. Sapiens (genetically modified human lymphocytes)

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known